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Purpose: This paper aimed to present daily-practice recommendations for the management 
of diabetic macular edema (DME) patients based on available scientific evidence and the 
clinical experience of the consensus panel.
Methods: A group of Spanish retina experts agreed to discuss different aspects related with 
the clinical management of DME patients.
Results: Panel was mainly focused on therapeutic objectives in DME management; defini-
tion terms; and role of biomarkers as prognostic and predictive factors to intravitreal 
treatment response. The panel recommends to start DME treatment as soon as possible in 
those eyes with a visual acuity less than 20/25 (always according to the retina unit capacity). 
Naïve patient was defined, in a strict manner, as a patient who, up to that moment, had never 
received any treatment. A refractory DME patient may be defined as the one who did not 
achieve a complete resolution of the disease, regardless of the treatment administered. 
Different optical coherence tomography biomarkers, such as disorganization of the retinal 
inner layers, hyperreflective dots, and cysts, have been identified as prognostic factors.
Conclusion: This document has sought to lay down a set of recommendations and to 
identify key issues that may be useful for the daily management of DME patients.
Keywords: diabetes, diabetic macular edema, optical coherence tomography, inflammation, 
biomarkers, consensus
Introduction
As the prevalence of diabetes mellitus is rising up, the importance of diabetic eye 
disorders increases.1,2 In Europe, it was estimated that approximately 6.4 million 
people are currently affected by any diabetic eye disease and 8.6 million people will 
be affected in 2050.3 In the year 2020, moderate-to-severe visual impairment due to 
diabetic retinopathy has been estimated in 4.06% (Western Europe); 4.77% (Asia- 
Pacific, high income); and 4.99% (United States, high income).2
Diabetic macular edema (DME) is a prevalent condition that impacts central 
visual acuity (VA), and, therefore, critically influence on patient’s quality of life.4,5
The prevalence of DME in Europe was estimated in 3.7% and its pooled mean 
annual incidence in type-2-diabetes patients was 0.4%.3
The changes in the paradigm of DME treatment6–11 as well as the development 
of technological advances for diagnosis12–15 makes, from our point of view, neces-
sary to reconsider the approach to the daily practice management of these patients.
The aim of this manuscript is to evaluate and respond to different issues related 
to the management of DME patients and to establish consensus-based recommen-
dations to provide the ophthalmologists responsible for the management of diabetic 
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patients with a frame of reference based on available 
scientific evidence and the clinical experience of the 
group.
Methods
A group of ophthalmologists in charge of Retina Units 
from 11 Spanish hospitals, working in collaboration, has 
developed a consensus report about different issues related 
to clinical management of patients with DME.
In the first meeting, performed on 13 February 2019, 
the panel of retina experts selected and agreed a first list of 
topics related to the clinical management of DME patients. 
The different subjects that focused the panel’s attention 
were as follows: 1) Therapeutic objectives in DME man-
agement; 2) Definition of naïve, refractory, and chronic 
DME; and 3) Role of biomarkers as prognostic and pre-
dictive factors to intravitreal treatment response.
Attending to these subjects, the expert panel developed 
a list of questions. These questions were discussed, 
updated literature was reviewed and responses were 
agreed in different meetings held from February to 
October 2019 (six meetings in total).
A PubMed literature search for English, French, and 
Spanish language articles published to date was performed 
using the terms “Diabetic macular edema” AND 
“Treatment” OR “Diagnosis” OR “Biomarkers” OR 
“Management” OR “Outcomes”. References cited in 
selected articles were also reviewed to identify additional 
relevant reports. Likewise, published national and interna-
tional guidelines were also scrutinized.
An initial document was drafted and it was reviewed 
by all members of the panel of experts, who had the 
opportunity to make all the changes/suggestions/comments 
deemed necessary. Finally, after making the required revi-
sions based on the panel feedback and reached 
a consensus, the final text was then validated.
Results
Basic Concepts
Therapeutic Objectives in DME
Functional and anatomic outcomes are usually selected as 
therapeutic objectives.16–34 While therapeutic objectives 
have been clearly defined in clinical trials, the identical 
criteria may not be applicable to routine clinical practice. 
Sometimes the objective of DME treatment is reduced to 
maintain VA. However, our treatment goals with DME 
patients should be more ambitious than that with 
neovascular age-related macular degeneration patients. 
There is some evidence suggesting that functional 
response critically depends on baseline VA, because 
patients with good visual acuity have a ceiling effect 
with limited visual improvement, and the status of retina 
as there are patients with retinal damage without any 
possibility of functional improvement and the stabilization 
of vision avoid the vision loss is an achievement.20,21,35 
Thus, our therapeutic objective in terms of vision 
should be:
● In patients with VA 20/25 or better: observation and 
start to treat if vision worsens.
● In patients with high baseline VA (20/40 to 20/32): 
To maintain the VA.
○ Although many clinicians initiate vascular 
endothelial growth factor inhibitors (anti-VEGF) 
treatment in DME patients when visual acuity is 
minimally affected or unaffected, Protocol V35 
found that, in eyes with central involved DME 
and good vision, visual acuity remained stable, at 
least, during 2 years. That is why, our main goal is 
maintaining VA and, as a secondary objective, to 
improve it, if possible.
● In patients with low baseline VA (20/50 to 20/320): 
To improve the VA.
On the other hand, and since functional response depends 
on the status of the retina,36–41 the efficacy of a treatment 
cannot be measured just attending to functional response. 
It has been suggested that in eyes with DME, VA depends 
on retinal thickness42 and integrity of retinal structure 
(including inner and outer retina layer), especially the 
photoreceptor layer.43–45 Because the functional response 
depends on the anatomic status of the retina, from a daily 
practice perspective, the main therapeutic objective in 
DME patients should be to achieve the best anatomic 
response as fast as possible, and at that point we must 
check the maximum functional response the patient 
can get.
It should be taken into consideration that an early 
anatomic response may predict mid-to-long-term anatomic 
outcomes and, therefore, the functional ones.46
When Patients Should Be Treated?
The results of Protocol V, a prospective and randomized 
clinical trial that compared three different strategies, 
namely intravitreal aflibercept, focal/grid laser 
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photocoagulation, or observation, suggested that in eyes 
with DME and good VA, aflibercept or laser photocoagu-
lation appeared to be no superior to observation at 2 
years.35
Moreover, the OBTAIN study, was as a 12-month, 
retrospective, multicenter, and observational cohort study 
conducted in a real-world setting, which included DME 
patients with baseline visual acuity ≥ 20/25 Snellen and 
central subfield thickness (CST) > 250 µm.47 Among the 
249 eyes included in the study, 94 eyes (37.7%) did not 
receive any treatment during 12 months of follow-up, and 
155 eyes (62.2%) received treatment over the course of the 
study. Mean change in VA at the end of the study was −  
1.8 ± 5.6 letters and − 3.4 ± 5.8 letters in non-treated and in 
treated eyes, respectively.47 The results of this study sug-
gested that most of the DME eyes with very good VA 
maintained that VA during the 12-month of follow up, 
whether the DME was treated or not.47
Although according to the results of the Protocol V35 
observation until vision deterioration occurs seems to be 
a feasible approach in DME with good baseline VA, these 
findings may not be applicable to all eyes with DME with 
good VA.48 For example, mean CST was very low (311 
μm) as compared with previous DME clinical trials. This 
is clinically relevant, since eyes with CST ≥400μm may 
have a different treatment response than eyes with 
a thinner CST.49
Real-life treatment patterns in newly diagnosed DME 
patients were evaluated by means of an analysis of the 
American Academy of Ophthalmology Intelligent 
Research in Sight (IRIS®) Registry.50 A total of 13,410 
treatment-naive DME patients were included in the analy-
sis. The results of this study have found that the treatment 
patterns within 28 days of initial DME diagnosis were as 
follows: observation in 9990 (74.5%) patients; anti-VEGF 
in 2086 (15.6%); laser photocoagulation in 1133 (8.4%); 
corticosteroids in 133 (1.0%); and combined therapy in 68 
(0.5%) patients.50
In daily practice, DME treatment does not represent an 
emergency. Nevertheless, because the presence of subret-
inal/intraretinal fluid may negatively impact on functional 
outcomes, early treatment would be highly 
recommended.51
Panel recommendation:
● When visual acuity is less than 20/25 DME treatment 
should begin as soon as possible, according to the 
capacity of the Retina Unit. The best scenario is one 
where patients are treated on the same day of diag-
nosis. However, the best scenario is rarely the most 
frequent. Therefore, in those cases in which patients 
cannot be treated on the same day, treatment should 
be administered within 10–15 days.
Definitions
What is DME?
DME can be defined as a retinal thickening (≥250 µm) 
within one disk diameter of the center of the macula or 
definite hard exudates in this region.16
If fovea is involved, we speak about “Center-involved 
DME”.16
Eyes with central macular thickness (CMT) ≥500 µm, hard 
exudates within 500 μm of the center of the macula with 
adjacent retinal thickening, or one disk area of retinal thicken-
ing any part of which is within one disk diameter of the center 
of the macula are defined as “Clinically relevant DME”.52
What is a Naïve Patient?
In the strictest agreement with the term, the panel defined 
a naïve patient as
● A patient who, up to that moment, had never received 
any treatment (pharmacological, laser, and/or surgical).
However, sometimes, it might be considered a naïve 
patient when he/she has received non-macula involved 
laser photocoagulation. In other words, would be a naïve 
patient for either intravitreal therapy with anti-VEGF and/ 
or steroids or grid macular laser.
Have Patients Treated with Anti-VEGF a Different 
Profile Than Those Treated with Sustained Released 
Corticosteroid Devices?
The panel agreed that there are not different types of naïve 
patients, but rather different kinds of patients. Having said 
that, it is important to take into consideration that there are 
different profiles of naïve patients according to their dis-
ease evolution; metabolic control; retinal thickness, and/or 
visual acuity. Therefore, the therapeutic response will cri-
tically depend on the clinical and demographic patient 
characteristics.6–11
What is a Refractory Patient?
A DME refractory patient may be defined as the one who 
did not achieve a complete resolution of the disease, 
regardless of the treatment administered.52–56
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Nevertheless, since anti-VEGF agents are broadly used 
as first-line therapy, the panel focused on the definition of 
DME patient’s refractory to anti-VEGF or DME patients 
who do not adequately respond to anti-VEGF therapy.
● Patient refractory to anti-VEGF: A patient that after 
loading dose (three consecutive monthly injections), 
shows no improvement in visual acuity (>5 ETDRS 
letters) and a ≤10% reduction of the central foveal thick-
ness measured by optical coherence tomography 
(OCT).56 In a strict manner, the anatomical non- 
improvement could be defined as a thickness reduction 
<20% of CST.
Although we have defined a patient refractory to anti- 
VEGF as a patient that after three consecutive monthly 
injections of anti-VEGF showed no functional and ana-
tomic improvement, according to data from Protocol T it 
seemed that maintaining anti-VEGF treatment for 24 
weeks might have positive outcomes on DME 
resolution.56 Therefore, extending the loading dose to 
five injections of intravitreal anti-VEGF, particularly with 
aflibercept, may be recommended.
What is a Chronic DME Patient?
To establish the definition of chronic DME is anything but 
easy.
We agreed to define chronic DME according to 
Bressler et al56 as
● Those eyes who did not achieve a CST < 250 μm 
and/or >10% reduction on at least two consecutive 
visits subsequent to the last follow-up visit.
Do the Different Patients’ Profiles Require Different 
Therapeutic Goals?
The panel members fully agreed that, in order to obtain the 
best results, it is necessary to individualize the therapeutic 
objectives according to the patient profile.
How Can We Define a Refractory ME? Does It 
Depend on the Patient Profile?
According to the Diabetic Retinopathy Clinical Research 
Network (DRCR.net)56 and panel opinion, a refractory ME 
can be defined as:
● A VA improvement (≤5 letters ETDRS) and a ≤10% 
reduction in CST (measured by OCT) . The anato-
mical non-improvement could be also defined as 
a thickness reduction <20% of CST.
Baseline patient profile may impact on treatment success: 
The better baseline characteristics (profile) the better treat-
ment response. Better baseline conditions include good 
VA; younger age; absence of vitreous retinal alterations, 
like epiretinal membranes; status of the outer retina, and 
grade of diabetic retinopathy.57
How Can We Define Lack of Treatment Response?
According to the panel members, after administration of 
three anti-VEGF intravitreal injections, a non-response to 
an intravitreal treatment would be defined as:
● Persistence or worsening of DME.
● Non-improvement in functional or anatomic 
outcomes.
Definition of Predictive and Prognostic Factor
Although the terms “predictive” and “prognostic” factors 
have been commonly used in many studies, they are sel-
dom defined and are often used interchangeably.58
About this subject, the definitions that reached 
a greater agreement among the panel members were:
● Prognostic factor: A characteristic that gives some 
information about the evolution of the patient. It can 
be helpful to guide the therapeutic approach. These 
factors are related to the evolution of the disease, and 
they are associated to the functional response that can 
be expected for the patient independently of the 
treatment administered.
● Predictive factor: A characteristic of the patient (clin-
ical, diagnostic, genetic, etc.) that gives some infor-
mation about the response (anatomical and/or 
functional) he/she will have to specific treatment. 
Predictive factors could be related to the probability 
of response to treatment.
OCT Biomarkers
Different OCT biomarkers, such as disorganization of the 
retinal inner layers (DRIL), hyperreflective dots (HRD), 
and epiretinal membranes may help clinicians to predict 
the effect of intravitreal therapy and may assist the choice 
of the pharmacological agent in the future.59
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Which Parameters Should Be Evaluated at Baseline in 
a DME Patient?
OCT parameters that are important to analyze at baseline 
visit
● CMT.
● Cysts (number, localization, and size).
● HRD (number and localization).
● Inner and outer retinal layers.
● Outer nuclear layer.
● Serous retinal detachment (SRD).
● Vitreo-retinal interface.
Serous Retinal Detachment (SRD)
Based on OCT examinations, it is possible to define three 
different morphologic subtypes of DME, namely sponge- 
like diffuse retinal thickening (DRT), cystoid macular edema 
(CME), and serous retinal detachment (SRD)60,61 (Figure 1).
It has been proposed an association between inflamma-
tion and the presence of SRD.62–64 Panel members agree 
with it. However, they consider that it is not clear whether 
the higher concentration of intravitreal cytokines is the 
cause or the consequence of SRD. Some papers propose 
a relationship between systemic diseases, such as chronic 
kidney disease, or glycemic control and SRD.65,66 Panel 
members do not consider SRD as a prognostic factor itself. 
However, long-term edemas usually present higher con-
centration of inflammatory cytokines and SRD is more 
frequent in this type of edemas. Therefore, SRD might 
be correlated with chronicity and worse type of edema.
Regarding the question of whether SRD is a predictive 
factor of response to intravitreal treatment, currently avail-
able scientific evidence provides conflicting results. While 
some studies have reported that the presence of SRD was 
associated with better functional and/or anatomic results to 
anti-VEGF treatments,39,67,68 others have reported no bet-
ter responsiveness with the same treatments.69–71
In addition, there is evidence suggesting that dexa-
methasone intravitreal (DEX) implants might provide bet-
ter functional and/or anatomic outcomes in eyes with 
SRD.38,40,72 In this sense, panel members recommend to 
use DEX implants rather than anti-VEGF for treating 
DME with SRD, especially the chronic ones. However, 
other factors, such as lens status, responsiveness to ster-
oids (elevation of intraocular pressure), and glaucoma 
should be taken into consideration.
Cystoid Macular Edema
Cyst formation begins with intercellular fluid accumula-
tion, although it is not clear if the cystoid spaces are 
intracellular or extracellular to the Müller cells.60,61,73,74
According to evidence and panel opinion, the presence 
of cysts is a marker of disease activity, chronicity of DME, 
and/or structural damage.56,75,76
Panel members agreed that, up to now, there is not 
enough scientific evidence to support the use of a specific 
treatment based on the number, size, or location of the cysts.
Figure 1 Spectral domain optical coherence tomography image of an eye with cystoid macular edema (CME) and serous retinal detachment (SRD).
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Additionally, they all agreed that large empty cysts are 
usually related to more advanced stages of the disease and 
may be a sign of chronicity. Therefore, DEX implants 
might be an option as first-line therapy.
Hyperreflective Dots (HRD)
The presence of HRD as image biomarkers has been 
suggested in DME.77 The role of the HRDs in predicting 
clinical outcomes in patients undergoing treatment for 
macular edema has shown controversial results. While 
some studies have shown that the presence of HRDs was 
associated with poorer visual outcome in patients with 
macular edema,78,79 one study reported that a higher num-
ber of HRDs at baseline was associated with an adequate 
treatment response.80
Although the etiology of HRDs has not been fully 
elucidated, retinal inflammation seemed to be involved.81 
Panel members agreed with it and based on this assump-
tion, DEX implant would be the treatment of choice.
However, they seem to be a marker of bad prognosis; 
therefore, the functional response might be limited.
Disorganization of the Retinal Inner Layers (DRIL) 
and Outer Retinal Layer (ORL)
DRIL
Disorganization of the retinal inner layers (DRIL) has 
been identified as a prognostic factor in DME patients.82,83 
In fact, there seems to be an association between DRIL 
resolution and best corrected VA (BCVA) 
improvement.82–84
Although the panel strongly recommended to assess 
the presence of DRIL at baseline, they are aware that it 
is not always easy to evaluate, that is why it is recom-
mended to evaluate DRIL at follow up visits (Figure 2A).
Additionally, DRIL used to be associated with damage 
on other retinal layers like ellipsoid zone (EZ) and external 
limiting membrane (ELM).83 Since the presence of DRIL 
indicates chronicity, panel members agree that treatment 
should be switched early if patient do not respond properly.
Recent scientific evidence has suggested that DEX 
implant may effectively ameliorate DRIL.85
Outer retinal layer (ORL)
ORL is the distance between ELM and retinal pigmen-
ted epithelium (RPE), which is the length of both inner 
and outer segment of the photoreceptor layer (Figure 2B 
and C). The main reason for delayed or incomplete visual 
recovery seems to be related to ultrastructural changes of 
the outer retinal layers.86–89 Although DME may be 
treated effectively in many eyes, outer retinal structures 
may remain irreversibly damaged in some patients.88
ELM integrity was associated with a final BCVA 
improvement in DME patients.88,89 This may suggest 
a significant relationship between ELM integrity and 
photoreceptor cell bodies’ status, which may be a sign of 
advanced photoreceptor damage.88,89 Moreover, ORL 
thickness correlates better with vision than the total retinal 
thickness.90–92
Additionally, in eyes with DME refractory to anti- 
VEGF therapy who received treatment with DEX implant, 
ORL disruptions might predict smaller VA gains if eval-
uated after an initial reduction of DME that DEX implant 
may effectively recover morphology of ORL in DME 
patients.93,94
Intercellular adhesion molecule-1 (ICAM-1) is an 
immunoglobulin that has been implicated in the develop-
ment of leukostasis, a relevant feature of DR.95 In fact, it 
has been suggested that both increased levels of VEGF 
and ICAM-1 are involved in DR development and are 
responsible of the ELM and of the inner segment and 
outer segment (IS/OS) junction disruption.95
Moreover, in patients with DME, intravitreal bevacizu-
mab has been associated with a restoration of the ELM, 
which was followed by a restoration of the EZ.96
In patients with uveitic cystoid macular edema, DEX 
implant was able to reverse ORL alterations.97 These 
findings were also observed in patients with macular 
edema associated with branch retinal vein occlusion.98
There is an increasing evidence suggesting that DEX 
implant may effectively recover the morphology of ORL 
in DME patients, which might be associated with better 
functional outcomes.93,94,99,100
Panel recommendation:
● ORL disruptions have a stronger prognostic value 
than DRIL in eyes with DME.
● Since ORL plays an important role as prognostic 
factor, it needs to be assessed at baseline. Despite 
the advances in OCT technology, in patients with 
“big DME”, it could be difficult to properly evaluate 
all the layers, so it would be necessary to reassess at 
follow-up visit. If ORL does not improve at all after 
one DEX implant, panel members agree that func-
tional prognosis is very poor.
● Despite the promising results obtained with DEX 
implants, more evidence would be needed determin-
ing the best treatment option in DME eyes with 
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DRIL/ORL. Nevertheless, it should be taken into 
consideration that DEX implant provides a rapid ana-
tomic response, which might facilitate an adequate 
assessment of ORL status.
Outer Nuclear Layer
The outer nuclear layer (ONL) contains the rod and cone 
cell bodies. ONL thickness is increased in diabetic 
patients.101,102 ONL damage is a marker of bad visual 
Figure 2 Spectral domain optical coherence tomography images. (A) Disorganization of the retinal inner layers (DRIL). It is not easy to identify the boundaries of the inner 
layers (white dotted line). Additionally, it is possible to see cysts (Cy) and hyperreflective dots (HD) in the outer layers, as well as the posterior hyaloid (PHL). (B) 
Spongiform edema with damage in the outer (ORL) and inner (INL) retinal layers. Besides the presence of cysts (Cy), it is possible to identify the external limiting membrane 
(ELM), and ellipsoid zone (EZ) disruptions. (C) Cystoid macular edema with external limiting membrane disruptions (ELMD). Additionally, it is possible to see some damage 
in the ellipsoid zone (EZ) and some cysts (Cy). 
Abbreviation: ORL, outer retinal layers.
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prognosis in DME patients and therefore the functional 
response is usually limited.89,103,104
It has been suggested that DEX implant may 
recover morphology of ONL in DME patients, which 
was associated with better functional outcomes.104 
However, further research is needed to confirm this 
finding.
Panel recommendation:
● Since functional response is usually limited in 
DME with ONL damage, intravitreal anti-VEGF 
injections or DEX implant could be indistinctly 
used as first-choice therapy. ONL alterations may 
be considered as a sign of bad prognosis. There is 
evidence suggesting that DEX implant might 
recover ONL damage, which, therefore, was asso-
ciated with better functional outcomes.104 
However, further research is needed to confirm 
this finding.
Central Macular Thickness
Although CMT reduction, measured with OCT, is a very 
useful marker and is commonly used for monitoring treat-
ment response in eyes with DME, there is not enough scien-
tific evidence to support the relationship between CMT and 
chronicity or CMT and inflammation in DME.6–15,40,41
Panel recommendation:
● CMT has to be assessed at baseline. DEX implant 
may be a first choice in eyes with diffuse DME, since 
they may be associated with a greater inflammatory 
component.105 Additionally, there is evidence sug-
gesting a significant association between macular 
thickness and the concentration of inflammatory mar-
ker ICAM-1.106 However, other factors need to be 
considered to decide the best treatment option.
Table 1 summarizes the main findings and comments of 
the panel regarding biomarkers.
Table 1 Overview of the Role of the Different Biomarkers Comments are based on the expert panel members experience as well as 
currently available scientific evidence [see references60–106]









SRD Yes Good/bad prognosis (depends on time 
course and other biomarkers)
No Yes Yes
CYSTS No (cysts with Hyperreflective 
material inside, have a greater 
inflammatory component)
Good/bad prognosis (depends on number, 
size, location and chronicity. Dense content 
is a sign of better prognosis)












DRIL No Bad prognosis Yes No No
ORL No Bad prognosis Yes No No
ONL No Bad prognosis Yes No No (DEX and anti- 
VEFG 
indistinctively)




Yes (in cases with 
high TMV)
Notes: *Its presence is a sign of … + big volume. 
Abbreviations: DEX, dexamethasone intravitreal implant; SRD, serous retinal detachment; HRD, hyperreflective dots; DRIL, disorganization of the retinal inner layers; 
ORL, outer retinal layer; ONL, outer nuclear layer; CMT, central macular thickness; anti-VEGF, vascular endothelial growth factor inhibitors; TMV, total macular volume.
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As therapeutic objectives, the panel recommended in 
patients with good baseline VA to maintain it and improve 
it if possible, taking into account the ceiling effect, and in 
patients with low baseline VA to improve it as much as 
possible except in patients with severe retinal damage that 
could limit the functional improvement; in those cases, 
maintenance of vision should be the main objective. From 
a daily practice perspective, the panel recommended, as 
main therapeutic objective to achieve the best anatomic 
response as fast as possible, and at that point we have to 
check the maximum functional response the patient can get.
According to the panel, DME treatment should start at 
soon as possible, according to the Retina Unit capability.
According to the panel, after administration of three 
anti-VEGF intravitreal injections, no response to an intra-
vitreal treatment would be defined as:
Persistence or worsening of DME and/or non- 
improvement in functional or anatomic outcomes.
Different biomarkers, including SRD, DRIL, cysts, 
HRD, ORL and ONL alterations, and CMT have been 
identified as prognostic and predictive factors in patients 
with DME. The panel recommended to assess these bio-
markers and take them into consideration when selecting 
the therapeutic strategy.
As a limitation of the current consensus, it should be 
mentioned the lack of discussion about costs-effectiveness 
of the different treatment options or social impact of both 
disease impairment and treatment. It is well known that 
both DME and diabetic retinopathy have a significant eco-
nomic impact due to their direct and indirect costs, includ-
ing reduction in income or an increased need for social 
support as vision worsens.107 Data about economic burden 
of DME in Spain suggested that the estimated direct 
annual cost per patient with DME was €6271 (excluding 
drug costs),108 while the estimated annual cost of treat-
ment with anti-VEGF was €7154.106,109
This consensus has highlighted different aspects related 
to the management of DME patients in daily clinical 
practice.
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